Corvidia
Corvidia Therapeutics is a privately held, clinical-stage biopharmaceutical company founded in 2014 in Waltham, Massachusetts, developing transformative therapies for cardio-renal diseases with a small R&D-focused team.
- Company typePrivate
- Founded2014
- HeadquartersWaltham, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Corvidia does
Corvidia Therapeutics is a privately held, clinical-stage biopharmaceutical company founded in 2014 and headquartered in Waltham, Massachusetts. The company focuses on the research and development of therapies targeting cardio-renal diseases — conditions at the intersection of cardiovascular and renal dysfunction — and operates with a small team of 11–50 employees. Its therapeutic approach is supported by a syndicate of specialized life-sciences investors, including Apple Tree Partners, Sofinnova Partners, Venrock, HBM Healthcare Investments, Cormorant Asset Management, Andera Partners, MedImmune, and Fresenius Medical Care, the latter two providing strategic exposure to biologics manufacturing and renal care delivery respectively.
The company's underlying technology centers on therapeutic candidates for cardio-renal indications, though specific molecules, mechanisms of action, and clinical trial stages are not detailed in the available data. The investor profile — particularly the participation of Fresenius Medical Care (a global dialysis leader) and MedImmune (AstraZeneca's biologics arm) — implies a development strategy aligned with biologics-based interventions and renal-care commercialization pathways. Corvidia has raised approximately $86.8 million across three disclosed funding rounds between 2016 and 2020.
Corvidia's business model is that of a pre-revenue R&D-driven biotech, monetizing not through commercial product sales but through eventual licensing, partnership, or M&A transactions with larger pharmaceutical or specialty care companies. Its near-term revenue mechanics rely on continued capital raises and strategic partnerships rather than product revenue. The company is led by Chairman Sylvie Gregoire; broader executive leadership and detailed operational data are not disclosed in the available source material.
Corvidia firmographics
Firmographics- Name
- Corvidia
- Website
- https://corvidiatx.com
- Company type
- Private
- Founded year
- 2014
- Headcount range
- 11–50 employees
- Short description
- Corvidia Therapeutics is a privately held, clinical-stage biopharmaceutical company founded in 2014 in Waltham, Massachusetts, developing transformative therapies for cardio-renal diseases with a small R&D-focused team.
- Ownership category
- akta.pro rank
Corvidia industry classification
Industry- Product category
- Cardio-Renal Therapeutics
- akta.pro primary industry
- Cardiac Assist & Heart Failure Therapies (Implantables, Neuromodulation) (HLAHAFAL)
Keywords
Where Corvidia is headquartered
LocationHeadquarters
- HQ city
- Waltham
- HQ country
- United States
- HQ region
- North America
Markets served
Corvidia business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Others
Corvidia product offering
Product offeringCore offering
Corvidia Therapeutics is a clinical-stage biopharmaceutical company focused on the research and development of transformative therapies for cardio-renal diseases. The company develops novel therapeutic compounds targeting cardiovascular and renal conditions, an area of significant unmet medical need.
Differentiator
Problem solved
Functional benefit
Companies that use Corvidia
Customer profileIdeal customer profiles1 record
Corvidia technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Corvidia partnerships and signals
Strategic signalRecent moves5 records
Expansion highlights4 records
Corvidia competitors and assessment
Company assessmentDirect peers
- Ardelyx, Inc. Ardelyx develops therapeutics for renal diseases, including CKD and dialysis-related indications — a directly comparable cardio-renal-adjacent biotech targeting kidney patients with high CV comorbidity.
- Akebia Therapeutics: Akebia Therapeutics focuses on anemia of CKD (vadadustat) — a cardio-renal therapeutic area sharing the same patient population (CKD patients with elevated CV risk) and overlapping clinical trial design.
- Relypsa (a Vifor Pharma company): Relypsa developed patiromer for hyperkalemia in CKD and CV patients — a textbook cardio-renal therapeutic; acquired by Galenica/Vifor. Closely comparable therapeutic, patient population, and indication strategy to a cardio-renal biotech.
- Tricida, Inc. Tricida developed veverimer for metabolic acidosis in CKD, with explicit CV outcomes rationale — a directly comparable small-molecule cardio-renal story at similar development stage and patient population.
- Keryx Biopharmaceuticals: Keryx developed ferric citrate for hyperphosphatemia in CKD/dialysis patients (later acquired by Akebia) — a direct comparable cardio-renal biotech with a similar focused-kidney-disease profile and small-cap exit path.
Emerging players
- Lexicon Pharmaceuticals: Lexicon develops sotagliflozin for heart failure and CKD — overlapping cardio-renal indication footprint and similar small-public-company development-stage profile to Corvidia.
- ProKidney Inc. ProKidney develops cell-therapy approaches for CKD, targeting the same cardio-renal patient population with a novel modality — comparable strategic interest of CV-pharma buyers for kidney disease assets.
- Cara Therapeutics: Cara Therapeutics developed difelikefalin for chronic kidney disease–associated pruritus in dialysis patients and explored CV/renal indications — directly overlapping cardio-renal therapeutic focus and small-cap biotech profile.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat4 records
Key risks5 records
Key highlights6 records
Customer concentration
Corvidia social profiles
Digital presenceCorvidia financial estimates
Financial estimateRevenue estimate
Valuation estimate
Corvidia leadership team
Management profileNumber of profiles
Profiles1 record
Corvidia funding detail
Funding detailFunding overview
Funding rounds3 records
Investors9 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Corvidia M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Corvidia
What does Corvidia do?
Corvidia Therapeutics is a clinical-stage biopharmaceutical company focused on the research and development of transformative therapies for cardio-renal diseases. The company develops novel therapeutic compounds targeting cardiovascular and renal conditions, an area of significant unmet medical need.
When was Corvidia founded?
Corvidia was founded in 2014. It employs 11 to 50 people.
Where is Corvidia based?
Corvidia is headquartered in Waltham, United States, in the North America region.
Who are Corvidia's main competitors?
Direct peers on record are Ardelyx, Inc., Akebia Therapeutics, Relypsa (a Vifor Pharma company), Tricida, Inc. and Keryx Biopharmaceuticals. Emerging players are Lexicon Pharmaceuticals, ProKidney Inc. and Cara Therapeutics.
Does Corvidia have an API?
No public API is recorded for Corvidia.
What industry is Corvidia in?
Corvidia's product category is Cardio-Renal Therapeutics. Its primary akta.pro industry code is HLAHAFAL, Cardiac Assist & Heart Failure Therapies (Implantables, Neuromodulation).